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Table 1
Biomarkers Hazard Ratio (95% CI)
uNTX-I 1.80 (0.83, 3.90
uCTX-II 2.28 (1.00, 5.16)
uC2C 1.06 (0.57, 1.97)
uC1,2C 1.29 (0.88, 1.89)
sHA 1.44 (0.79, 2.63)
sCS846 1.32 (0.49, 3.56)
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S156between BP use and age, sex, joint replaced (hip/knee), and prior frac-
ture on outcome by introducing multiplicative terms in the equation.
Results: 80,342/95,392 (84.2%) subjects were eligible. We identiﬁed
1,950 (2.4%) BPU, and 1,911 (98.0%) of them were matched to 10,755
BPNU. In total, 226/12,666 (1.78%) of the participants (22/1,911 BPU and
204/10,755 matched BPNU) underwent revision surgery during study
follow-up (median 1.11 years, inter-quartile range 0.43-2.29 years).
Cox regression models showed reduced revision risk in BP users
(propensity-matched HR 0.59; 95% Conﬁdence Interval (CI) [0.37-0.94])
[Figure], which remained signiﬁcant after multivariable adjustment for
unbalanced covariates (adjusted HR 0.59; 95% CI [0.37-0.93]). This
protective effect was only seen in BPU who initiated treatment post-
operatively (adjusted HR 0.36 ; 95% CI [0.15-0.84]) and not in those
starting pre-op (adjusted HR 0.77; 95% CI [0.44-1.35]), and who
remained on treatment for at least one year: adjusted HR 0.50; 95% CI
[0.27-1.00] for those treated for 1-2 years compared to adjusted HR
1.29; 95% CI (0.80-2.08) in those treated for 6-12 months. Patients with
the highest adherence beneﬁted the most (adjusted HR 0.53; 95% CI
(0.30-0.95)) in BPU with MPR>0.8).
The effect of BPU on implant survival was not modiﬁed by age, gender,
fracture history or joint replaced (all p for interactions>0.2).
Conclusions: BPU are at 40% reduced risk of revision compared to
matched BPNU. These results are similar to previous ﬁndings using
similar retrospective data from the UK [Prieto-Alhambra D et al. BMJ
2011]. Conﬁrmation of these beneﬁcial effects in formal randomized
controlled trials is urgently needed.Ă
sCPII 0.58 (0.34, 0.99)
sCOMP 2.58 (0.48, 13.90)
sC2C 0.53 (0.15, 1.87)
sC1,2C 1.61 (0.52, 4.94)
uCTX-II/sCPII 1.78 (1.17, 2.72)
uC2C/sCPII 1.44 (0.93, 2.21)
uC1,2C/sCPII 1.52 (1.08, 2.16)
sC2C/sCPII 2.15 (1.05, 4.39)293
ASSOCIATION OF BIOMARKERS WITH OSTEOARTHRITIS
PROGRESSION BASED ON MRI: RESULTS FROM THE VANCOUVER
KNEE OSTEOARTHRITIS PROGRESSION (KOAP) STUDY
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Purpose: To determine the association of biomarkers with progression
of osteoarthritis (OA), based on MRI, in a population-based cohort of
predominantly pre-radiographic disease.
Methods: Population-based longitudinal cohort study of subjects, age
40 to 79, with knee pain. Subjects were evaluated at baseline and
follow-up (FU) using detailed clinical assessments, knee x-ray, MRI
(1.5T) and biomarkers. MRI of cartilage (MRC) was scored 0-4 on six
joint surfaces. Progression was deﬁned on MRI as an increase in MRC
score of 1 grade on at least 2 cartilage surfaces or an increase of MRC
score of 2 grades on at least 1 cartilage surface. Urine biomarkers
included C-telopeptide of type II collagen (uCTX-II) (Nordic Bioscience),
type II and type I and II collagen cleavage neoepitopes (uC2C, uC1,2C)
(Ibex), N-telopeptide of type I collagen (uNTX-I) (Ostex). Serum
biomarkers included sC1,2C, sC2C, c-propeptide of type II procollagen(sCPII), 846 epitope (sCS846) (Ibex), cartilage oligomeric matrix protein
(sCOMP) (AnaMar) and hyaluronic acid (sHA) (Corgenix). Ratios of type
II collagen degradation with synthesis markers were also evaluated.
Biomarker data were log transformed. Exponential regression analysis
was used to determine the association of each biomarker with OA
progression, adjusted for age, gender, BMI and joint count. All analyses
utilized longitudinal stratum sampling weights to ensure generaliz-
ability of results.
Results: Of 255 subjects seen at baseline, 163 (63.9%) were assessed at
a median FU of 3.2 years (range 2.5-5.1). Of these, 60.6% had KL grade
<2, mean age was 57.6 years. MRI progression was present in 15.5% of
subjects. Biomarkers signiﬁcantly associated with OA progression
included uCTX-II (HR 2.28; 95% CI 1.00, 5.16), sCPII (HR 0.58; 95% CI 0.34,
0.99), as well as ratios of uCTX-II/sCPII (HR 1.78; 95% CI 1.17, 2.72),
uC1,2C/sCPII (HR 1.52; 95% CI 1.08, 2.16) and sC2C/sCPII (HR 2.15; 95% CI
1.05, 4.39) (Table 1).Conclusions: In this population-based cohort of predominantly pre-
radiographic knee OA, uCTX-II and sCPII were both signiﬁcantly asso-
ciated with OA progression. As well, ratios of uCTX-II/sCPII, uC1,2C/sCPII
and sC2C/sCPII were signiﬁcantly associated with OA progression with
similar strengths of association. These biomarkers may be useful in
future studies aimed at evaluating OA disease progression in epidemi-
ologic studies and clinical trials.
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Purpose: To determine the clinical predictors of osteoarthritis (OA)
progression based on cartilage damage on MRI in a population-based
cohort of predominantly pre-radiographic knee OA and to develop
a simpliﬁed model to identify those at risk of progression with high
speciﬁcity for practical application in clinical trials.
Methods: Population-based longitudinal cohort study of subjects, age
40 to 79, with knee pain. Subjects were evaluated at baseline and
follow-up (FU) using detailed clinical assessments, standardized knee
examination, ﬁxed-ﬂexion knee x-ray and MRI (1.5T). X-rays were read
for Kellgren-Lawrence (KL) 0-4 grade. MRI of cartilage (MRC) was
scored 0-4 on six joint surfaces by a blinded reader. OA progression was
deﬁned on MRI as an increase in MRC score of 1 grade on at least 2
cartilage surfaces or an increase in MRC score of 2 grades on at least 1
cartilage surface. Exponential regression analysis was used to develop
a prediction model for OA progression. The model was evaluated based
on prediction accuracy, Akaike's Information Criterion (AIC) and C-
index, where a 1.0 score indicates a perfect model ﬁt. The model was
then simpliﬁed by removing variables and evaluating the impact on the
model accuracy and C-index. All analyses utilized longitudinal stratum
sampling weights to maintain generalizability.
Results: Of 255 subjects seen at baseline, 163 (63.9%) were assessed at
a median FU of 3.2 years (range 2.5-5.1). Of these, 60.6% had KL grade
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S157<2, mean age was 57.6 years. MRI progression was present in 15.5% of
subjects. In the full prediction model, nine variables were retained,
including injury (none, mild, severe), KL grade (0-4), quadriceps
weakness (no/yes), patellofemoral (PF) grind test (no/yes), patellar pain
(no/yes), lateral tibiofemoral (TF) tenderness (no/yes), gait (normal/
abnormal), crepitus (none, ﬁne, coarse) and hand OA (no/yes). The
simpliﬁed model contained 5 variables and had excellent speciﬁcity
with good positive and negative predictive values (Table 1).Table 1
Full 9-variable
model
Simpliﬁed 5-variable
model
Predictive accuracy 92.6% 85.9%
Sensitivity 63.0% 18.5%
Speciﬁcity 98.5% 99.3%
Positive predictive value 89.5% 83.3%
Negative predictive value 93.1% 86.0%
C-index 0.91 0.85
The variables in the ﬁnal simpliﬁed 5-variable model included PF grind test (HR
0.12; 95% CI 0.02-0.63), quadriceps weakness (HR 8.78; 95% CI 2.95-26.18), KL grade
 1 (HR 6.86; 95% CI 1.65-28.51), lateral TF tenderness (HR 0.41; 95% CI 0.14-1.18)
and history of knee injury (HR 4.21; 95% CI 1.52-11.70).
Table
Estimates of four-year percent weight change applying different methods for handling missing data, and associations with selected characteristics among obese adults with
radiographic KOA
Complete case
(N¼933)
3YR percent weight change
carried forward (N¼1018)
Last observation carried
forward (N¼1132)
Multiple imputation
(N¼1132)
Mean (SD) p-value Mean (SD) p-value Mean (SD) p-value Mean (SD) p-value
Full sample -0.7 (7) -0.7 (7) -0.8 (6.9) -0.8 (7.0)
Age
45-54 years
55-64 years
65-79 years
0.2 (8.0)
-0.9 (6.9)
-1.3 (6.2)
0.035 0.3 (8.0)
-1.0 (7.0)
-1.2 (6.1)
0.014 0.4 (8.0)
-1.0 (6.8)
-1.3 (6.0)
0.003 0.1 (7.8)
-0.9 (6.9)
-1.3 (6.3)
0.046
Sex
Female
Male
-0.8 (7.5)
-0.6 (6.2)
0.591 -0.8 (7.4)
-0.7 (6.2)
0.803 -0.8 (7.4)
-0.7 (6.1)
0.839 -0.9 (7.4)
-0.7 (6.3)
0.655
Charlson
Comorbidity
Index
0
1
2+
-0.5 (6.7)
-0.8 (6.9)
-1.9 (8.1)
0.156 -0.5 (6.7)
-0.7 (6.9)
-2.1 (8.0)
0.068 -0.5 (6.7)
-0.8 (6.8)
-1.8 (7.5)
0.105 -0.6 (6.8)
-0.5 (7.0)
-2.2 (7.8)
0.051Conclusions: In this population-based cohort of predominantly pre-
radiographic knee OA, progression of OA can be predicted accurately
using 3 knee clinical features, history of injury and x-ray results. The
simpliﬁed model retains excellent speciﬁcity and has the ability to rule
in 83.3% of OA progressors and rule out 86.0% of non-progressors.
Compared to the use of MRI, this simpliﬁed model may be a cost-
effectiveway to recruit subjects at risk of progression into future clinical
trials, aimed at the evaluation of efﬁcacy of disease-modifying agents.295
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Purpose: Attrition can threaten the validity of longitudinal studies. In
clinical trials and observation studies focusing on weight change,
attrition is often differential by weight loss or lack thereof. The purpose
of this study was to evaluate the impact of attrition on estimates of four-
year weight change among obese adults with radiographic knee oste-
oarthritis (KOA) in the national Osteoarthritis Initiative (OAI).
Methods: We included 1132 participants with radiographically-
conﬁrmed KOA who were obese (body mass index >¼30 kg/m2) atbaseline. Age, sex, and comorbidities (Charlson Comorbidity Index) were
assessed at baseline.We calculated four-year percentweight change (YR4
to baseline), and compared mean weight change across participant
characteristics. We compared the complete case analysis to three
approaches to imputing missing four-year percent weight change: (1)
percent weight change from baseline to YR3, which assumes no weight
change from YR3 to YR4; (2) last observation carried forward approach
using themost recent availableweight (YR3, YR2, or YR1), which assumes
no weight change since this measurement; and (3) multiple-imputation
of four-year percent weight change based on age, sex, Charlson Comor-
bidity Index, and study site. Analyses were conducted using SAS 9.2.
Results: The sample was 27% aged 45-54 years, 36% 55-64 years, and
37% 65-79 years; 62% female; and a third had comorbidities (20% with
Charlson Comorbidity Index¼1, 13% ¼2+). Eighteen percent (n¼199)
were missing YR4 weight. Availability of YR4 weight differed by
Charlson Comorbidity Index (p¼0.003; 31% with available YR4 weight
vs 41% missing YR4 weight had comorbidities) but not by age (p¼0.113)
or sex (p¼0.286). Estimated mean four-year percent weight change and
associations with participant characteristics did not appreciably differ
by approach to handling missing YR4 weight (Table).
Conclusions: Attrition did not appear to impact estimates of and
associations with four-year weight change in a clinically meaningful
way. Nevertheless, this example illustrates four approaches to handling
attrition in longitudinal analyses using data from the OAI.296
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Purpose: Foot pain has been linked to poor outcomes, such as falls, poor
function and disability. High plantar pressures have also been shown to
contribute to foot pain and risk of falls. Higher body mass index (BMI)
and toe weakness have previously been associated with foot structure.
Little is known about how the foot might affect physical functioning or,
speciﬁcally, leg muscle mass. One prior study has examined the asso-
ciation between leg muscle mass and foot pain, structure or function
but examined only Caucasian participants. The purpose of this cross-
sectional analysis was to evaluate the relation of leg muscle mass to
these characteristics, in a community-based study of Caucasian and
African American men and women 50 years of age or older. We
hypothesized that foot symptoms and poor foot function/structure (e.g.
supination or pronation) would be linked to low leg muscle mass.
Methods: Johnston County Osteoarthritis Project participants with
complete data on leg muscle mass as well as foot pain, structure and
function data were included in this study. Whole body dual-energy X-
ray absorptiometry (DXA; Hologic) was used to measure leg muscle
mass (kg). Foot symptoms were present if pain, aching or stiffness was
reported on most days of the month. Data from a Tekscan Matscan
